US2020297791A1PendingUtilityA1

Suppression of antimicrobial protein levels

Assignee: UNIV LOUISIANA AT LAFAYETTEPriority: Jan 8, 2018Filed: Apr 23, 2020Published: Sep 24, 2020
Est. expiryJan 8, 2038(~11.5 yrs left)· nominal 20-yr term from priority
A61K 36/07A61K 9/006A61K 36/71A61K 36/73A61K 36/28A61K 36/76A61K 36/45A61K 36/8962A61K 36/87A61P 31/00A61K 36/52A61K 36/74
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Exercise is a stressor that is known to in some cases suppress antimicrobial protein levels, particularly secretory immunoglobulin type A (IgA). Athletes in the midst of in-season training often demonstrate low levels of sIgA and supplements may enhance post exercise mucosal immune function. A study was conducted where three treatments were administered (botanical spray, botanical drops, placebo) at the onset of 30 minutes of 80% V02 max cycle ergometer exercise. Secretory IgA and Human Alpha Defensin were quantified in saliva samples 30 minutes and 90 minutes post exercise. Analysis revealed a significant treatment effect at 30 min (p=0.030) with post hoc testing revealing a difference between the botanical spray and placebo (p=0.027), but by 90 minutes there was no differences by treatment (p=0.758). Based upon this study, it appears that a single dose of the tested botanical can provide enhanced mucosal immune capability for a short time post exercise.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for suppressing upper respiratory tract infection comprising administrating a dose of biocidin. 
     
     
         2 . The method of  claim 1 , wherein the dose of biocidin is administered prior to exercise. 
     
     
         3 . The method of  claim 1 , wherein the dose of biocidin is administered during exercise. 
     
     
         4 . The method of  claim 1 , wherein the dose of biocidin is administered after exercise. 
     
     
         5 . The method of  claim 1 , wherein the dose of biocidin is administered by spraying biocidin in the oral cavity.

Join the waitlist — get patent alerts

Track US2020297791A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.